| [1] |
Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)[J]. J Clin Oncol, 2021, 39(6): 619-630. DOI: 10.1200/JCO.20.01055.
|
| [2] |
Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 3. DOI: 10.1038/s41572-020-00235-0.
|
| [3] |
Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data[J]. Nat Rev Cancer, 2019, 19(5): 289-297. DOI: 10.1038/s41568-019-0133-9.
|
| [4] |
Schwendenwein A, Megyesfalvi Z, Barany N, et al. Molecular profiles of small cell lung cancer subtypes: therapeutic implications[J]. Mol Ther Oncolytics, 2021, 20: 470-483. DOI: 10.1016/j.omto.2021.02.004.
|
| [5] |
Qi J, Zhang J, Liu N, et al. Prognostic implications of molecular subtypes in primary small cell lung cancer and their correlation with cancer immunity[J]. Front Oncol, 2022, 12: 779276. DOI: 10.3389/fonc.2022.779276.
|
| [6] |
Megyesfalvi Z, Gay CM, Popper H, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions[J]. CA Cancer J Clin, 2023, 73(6): 620-652. DOI: 10.3322/caac.21785.
|
| [7] |
Motas N, Manolache V, Scarcim M, et al. Salvage surgery for small-cell lung cancer—a literature review[J]. Cancers (Basel), 2023, 15(8): 1-11. DOI: 10.3390/cancers15082241.
|
| [8] |
Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 3. DOI:10.1038/s41572-020-00235-0.
|
| [9] |
中国临床肿瘤学会指南工作委员会. CSCO小细胞肺癌诊疗指南[M]. 北京: 人民卫生出版社, 2024, 4: 1-134.
|
| [10] |
Hayes C. Cellular immunotherapies for cancer[J]. Ir J Med Sci, 2021, 190(1): 41-57.DOI: 10.1007/s11845-020-02264-w.
|
